Radioactive seeds aim to boost Chemo's punch against breast cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 to 70 years. * ECOG performance status 0-1. * Pathologically confirmed, previously untreated, unilateral primary invasive breast cancer. * Clinical stage cT1cN1-2M0 or cT2-3N0-2M0 (AJCC 8th edition). * Adequate organ function within 7 days prior to randomization: * Hemoglobin ≥ 90 g/L * ANC ≥ 1.5×10⁹/L; Lymphocyte count ≥ 0.5×10⁹/L * Platelet count ≥ 100×10⁹/L * WBC 3.0-15×10⁹/L * ALT, AST ≤ 2.5×ULN; ALP ≤ 2.5×ULN; TBIL ≤ 1.5×ULN * Serum creatinine ≤ 1.5×ULN and creatinine clearance ≥ 60 mL/min * PT, APTT ≤ 1.5×ULN * Urine protein \< 2+ or 24-hour urine protein ≤ 1 g * LVEF ≥ 55% * QTcF \< 470 ms * Negative serum pregnancy test within 3 days prior to first treatment for women of childbearing potential and agreement to use effective contraception. * Willing and able to sign informed consent. Exclusion Criteria: * Bilateral breast cancer or history of DCIS, LCIS, invasive breast cancer, or metastatic breast cancer. * Any malignancy diagnosed within the past 5 years except cured cervical carcinoma in situ or non-melanoma skin cancer. * Prior systemic chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 1 year. * Prior exposure to anthracyclines, taxanes, or platinum agents. * Primary or secondary immunodeficiency; uncontrolled autoimmune disease (except controlled hypothyroidism or type 1 diabetes). * Interstitial lung disease or severe chronic lung disease. * Clinically significant cardiovascular disease, including: * NYHA class ≥ III * Myocardial infarction or stroke within 3 months * Uncontrolled hypertension * Clinically significant arrhythmia or heart failure * Arterial/venous thrombosis within 3 months. * Vaccination with live attenuated vaccine within 28 days. * Active HBV, HCV, or HIV infection. * Major surgery within 28 days (except diagnostic procedures). * Severe infection within 4 weeks or systemic antibiotic-treated infection within 2 weeks. * History of bone marrow or organ transplantation. * Coagulation abnormalities (INR \> 1.5 or APTT \> 1.5×ULN). * Peripheral neuropathy ≥ Grade 2. * Treatment with systemic immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks. * Known allergy to study agents. * Participation in another clinical trial within 4 weeks. * Pregnancy, breastfeeding, or planning pregnancy. * Substance abuse or psychiatric conditions that may affect compliance. * Any condition that, in the investigator's judgment, makes the patient unsuitable for the study.